Centessa Pharmaceuticals plc (NASDAQ:CNTA) Receives $10.50 Consensus PT from Analysts

Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA) have earned a consensus recommendation of “Moderate Buy” from the six ratings firms that are covering the firm, Marketbeat reports. Two analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $10.50.

Several analysts have recently weighed in on CNTA shares. BMO Capital Markets reiterated an “outperform” rating and set a $15.00 target price on shares of Centessa Pharmaceuticals in a research report on Monday, April 1st. Morgan Stanley lifted their target price on shares of Centessa Pharmaceuticals from $8.00 to $11.00 and gave the company an “equal weight” rating in a research report on Friday, June 21st.

Centessa Pharmaceuticals Stock Performance

NASDAQ:CNTA opened at $9.93 on Wednesday. Centessa Pharmaceuticals has a 1 year low of $5.15 and a 1 year high of $12.45. The firm’s fifty day simple moving average is $8.97 and its 200 day simple moving average is $9.44. The company has a current ratio of 10.37, a quick ratio of 10.37 and a debt-to-equity ratio of 0.36. The firm has a market capitalization of $997.79 million, a PE ratio of -6.99 and a beta of 1.40.

Centessa Pharmaceuticals (NASDAQ:CNTA) last posted its earnings results on Monday, May 13th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.03. On average, sell-side analysts anticipate that Centessa Pharmaceuticals will post -1.67 EPS for the current year.

Institutional Trading of Centessa Pharmaceuticals

Institutional investors have recently made changes to their positions in the business. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Centessa Pharmaceuticals by 371.2% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,394 shares of the company’s stock worth $51,000 after buying an additional 5,037 shares during the period. Jump Financial LLC bought a new position in Centessa Pharmaceuticals in the 4th quarter valued at about $114,000. Trexquant Investment LP bought a new position in Centessa Pharmaceuticals in the 4th quarter valued at about $114,000. Franklin Resources Inc. raised its holdings in Centessa Pharmaceuticals by 34.1% in the 4th quarter. Franklin Resources Inc. now owns 1,115,817 shares of the company’s stock valued at $8,882,000 after acquiring an additional 283,469 shares during the period. Finally, Platinum Investment Management Ltd. raised its holdings in Centessa Pharmaceuticals by 12.9% in the 4th quarter. Platinum Investment Management Ltd. now owns 381,083 shares of the company’s stock valued at $3,033,000 after acquiring an additional 43,539 shares during the period. Institutional investors own 82.01% of the company’s stock.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its pipeline products include SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of NT1 with potential expansion into other sleep disorders.